In this study, our data indicate that RYR ameliorates HFD-induced hepatic steatosis and inflammation by inhibiting NF-κB/NLRP3 inflammasome signaling and SREBP pathways in vivo and in vitro. Here, NLRP3 is linked to Hepatic steatosis.